دورية أكاديمية
أعرض في EDS

Effects of neoadjuvant zoledronate and radiation therapy on cell survival, cell cycle distribution, and clinical status in canine osteosarcoma.

التفاصيل البيبلوغرافية
العنوان: Effects of neoadjuvant zoledronate and radiation therapy on cell survival, cell cycle distribution, and clinical status in canine osteosarcoma.
المؤلفون: Norquest CJ; Department of Veterinary Medicine & Surgery, University of Missouri College of Veterinary Medicine, Columbia, MO, United States., Rogic A; Department of Veterinary Medicine & Surgery, University of Missouri College of Veterinary Medicine, Columbia, MO, United States., Gimotty PA; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania School of Medicine, Philadelphia, PA, United States., Maitz CA; Department of Veterinary Medicine & Surgery, University of Missouri College of Veterinary Medicine, Columbia, MO, United States., Rindt H; Department of Veterinary Medicine & Surgery, University of Missouri College of Veterinary Medicine, Columbia, MO, United States., Ashworth HL; Department of Veterinary Medicine & Surgery, University of Missouri College of Veterinary Medicine, Columbia, MO, United States., Bryan JN; Department of Veterinary Medicine & Surgery, University of Missouri College of Veterinary Medicine, Columbia, MO, United States., Donnelly LL; Department of Veterinary Medicine & Surgery, University of Missouri College of Veterinary Medicine, Columbia, MO, United States., McCleary-Wheeler AL; Department of Veterinary Medicine & Surgery, University of Missouri College of Veterinary Medicine, Columbia, MO, United States., Flesner BK; Department of Veterinary Medicine & Surgery, University of Missouri College of Veterinary Medicine, Columbia, MO, United States.; Department of Clinical Sciences & Advanced Medicine, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, United States.
المصدر: Frontiers in veterinary science [Front Vet Sci] 2024 Jan 31; Vol. 11, pp. 1237084. Date of Electronic Publication: 2024 Jan 31 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101666658 Publication Model: eCollection Cited Medium: Print ISSN: 2297-1769 (Print) Linking ISSN: 22971769 NLM ISO Abbreviation: Front Vet Sci Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Lausanne : Frontiers Media S.A., [2014]-
مستخلص: Introduction: Zoledronic acid (ZOL) is a third-generation bisphosphonate with a higher affinity for bone resorption areas than earlier bisphosphonates (i.e., pamidronate, PAM). In human medicine, ZOL provides improved bone pain relief and prolonged time to skeletal-related events compared to its older generational counterparts. Preclinical studies have investigated its role as an anti-neoplastic agent, both independently and synergistically, with radiation therapy (RT). ZOL and RT act synergistically in several neoplastic human cell lines: prostate, breast, osteosarcoma, and fibrosarcoma. However, the exact mechanism of ZOL's radiosensitization has not been fully elucidated.
Methods: We investigated ZOL's ability to induce apoptosis in canine osteosarcoma cell lines treated with various doses of megavoltage external beam radiotherapy. Second, we evaluated cell cycle arrest in ZOL-treated cells to assess several neo-adjuvant time points. Finally, we treated 20 dogs with naturally occurring appendicular OS with 0.1 mg/kg ZOL IV 24 h before receiving 8 Gy of RT (once weekly fraction x 4 weeks).
Results: We found that apoptosis was increased in all ZOL-treated cell lines compared to controls, and the combination of ZOL and RT resulted in dissimilar apoptosis between Abrams and D-17 and HMPOS cell lines. Cell cycle arrest (G2/M phase) was minimal and variable between cell lines but perhaps greatest at 48 h post-ZOL treatment. Only 10% of dogs treated with ZOL and RT developed pathologic fractures, compared to 44% of dogs historically treated with PAM and RT ( p  = 0.027).
Discussion: ZOL and RT appear to be a well-tolerated combination treatment scheme for non-surgical candidates; future studies must elucidate the ideal timing of ZOL.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 Norquest, Rogic, Gimotty, Maitz, Rindt, Ashworth, Bryan, Donnelly, McCleary-Wheeler and Flesner.)
References: Lung Cancer. 2005 Jan;47(1):31-9. (PMID: 15603852)
Cancers (Basel). 2021 Jan 27;13(3):. (PMID: 33513745)
Bone. 2020 Aug;137:115390. (PMID: 32353565)
J Vet Intern Med. 2017 May;31(3):864-871. (PMID: 28378427)
Vet Clin North Am Small Anim Pract. 2007 Nov;37(6):1091-110; vi. (PMID: 17950884)
Bone. 2021 Jan;142:115711. (PMID: 33141069)
J Am Anim Hosp Assoc. 2002 Sep-Oct;38(5):445-51. (PMID: 12220029)
Pain Med. 2009 Jan;10(1):133-42. (PMID: 18823385)
Vet Med Sci. 2022 May;8(3):1013-1024. (PMID: 35263506)
J Vet Intern Med. 2016 Jul;30(4):1235-40. (PMID: 27296235)
JAMA. 2017 Jan 3;317(1):48-58. (PMID: 28030702)
Neoplasma. 2019 Sep;66(5):766-775. (PMID: 31288526)
Aust Vet J. 2023 Jan;101(1-2):58-64. (PMID: 36385598)
PLoS One. 2022 Sep 13;17(9):e0274383. (PMID: 36099278)
BMC Cancer. 2014 Mar 19;14:203. (PMID: 24641873)
J Vet Intern Med. 2008 Mar-Apr;22(2):380-7. (PMID: 18346146)
Anticancer Res. 2010 Jul;30(7):2713-20. (PMID: 20683003)
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):535-42. (PMID: 15667977)
Vet Comp Oncol. 2015 Sep;13(3):157-65. (PMID: 23489591)
J Cell Sci. 2000 Feb;113 ( Pt 3):377-81. (PMID: 10639325)
J Radiat Res. 2019 Mar 1;60(2):242-248. (PMID: 30445597)
Breast Cancer Res. 2006;8(4):R52. (PMID: 16925824)
Front Vet Sci. 2021 Jul 02;8:647846. (PMID: 34277751)
Nat Commun. 2015 Dec 03;6:8940. (PMID: 26632267)
Vet Comp Oncol. 2003 Dec;1(4):207-15. (PMID: 19379182)
Bonekey Rep. 2013 Feb 06;2:267. (PMID: 24422040)
Curr Opin Oncol. 2009 Nov;21(6):499-506. (PMID: 19730102)
Medicine (Baltimore). 2015 Oct;94(42):e1822. (PMID: 26496320)
Can J Vet Res. 2019 Jan;83(1):3-10. (PMID: 30670896)
J Cancer. 2011 May 04;2:262-70. (PMID: 21552385)
J Vet Med Sci. 1999 Apr;61(4):361-7. (PMID: 10342286)
Clin Cancer Res. 2021 Jun 1;27(11):3005-3016. (PMID: 33753454)
Lancet Oncol. 2019 Feb;20(2):267-281. (PMID: 30579763)
Clin Orthop Relat Res. 1991 Sep;(270):159-68. (PMID: 1884536)
Int J Clin Oncol. 2018 Dec;23(6):1127-1133. (PMID: 29959563)
Drugs. 2016 Nov;76(17):1683-1697. (PMID: 27864686)
Pract Radiat Oncol. 2017 Jan - Feb;7(1):4-12. (PMID: 27663933)
Vet Pathol. 2005 Mar;42(2):161-5. (PMID: 15753469)
BMC Vet Res. 2012 May 15;8:56. (PMID: 22587466)
Vet Comp Oncol. 2022 Dec;20(4):788-796. (PMID: 35561080)
J Bone Joint Surg Am. 1996 May;78(5):656-63. (PMID: 8642021)
PLoS One. 2021 Feb 8;16(2):e0246443. (PMID: 33556121)
J Vet Intern Med. 2009 Jan-Feb;23(1):152-60. (PMID: 19175734)
Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):13639-44. (PMID: 26483491)
Oncotarget. 2016 Oct 25;7(43):70869-70880. (PMID: 27765919)
J Small Anim Pract. 2005 Feb;46(2):65-70. (PMID: 15736811)
Animals (Basel). 2020 Oct 28;10(11):. (PMID: 33126659)
Vet Radiol Ultrasound. 2001 Sep-Oct;42(5):475-6. (PMID: 11678573)
Front Vet Sci. 2021 Dec 16;8:637195. (PMID: 34977203)
Vet Med Sci. 2023 Jan;9(1):59-67. (PMID: 36398717)
Int J Oncol. 2007 Aug;31(2):285-91. (PMID: 17611684)
فهرسة مساهمة: Keywords: cancer pain; osteosarcoma; pathologic fracture; radiation therapy; zoledronate
تواريخ الأحداث: Date Created: 20240216 Latest Revision: 20240217
رمز التحديث: 20240217
مُعرف محوري في PubMed: PMC10867971
DOI: 10.3389/fvets.2024.1237084
PMID: 38362299
قاعدة البيانات: MEDLINE
الوصف
تدمد:2297-1769
DOI:10.3389/fvets.2024.1237084